证券代码：301196 证券简称：唯科科技 编号：2022-002 厦门唯科模塑科技股份有限公司关于召开 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for Q3 2022 was CNY 243,108,595.72, a decrease of 22.97% year-over-year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 41,696,556.20, down 27.96% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses for Q3 2022 was CNY 29,875,822.20, a decline of 45.43% year-over-year[5] - Total operating revenue for Q3 2022 was CNY 704,529,147.89, a decrease of 22.7% compared to CNY 911,660,501.79 in the same period last year[27] - Net profit for Q3 2022 was CNY 116,656,880.85, a decline of 29.0% compared to CNY 164,324,874.43 in Q3 2021[28] - Basic earnings per share for Q3 2022 were CNY 0.9310, down from CNY 1.7045 in the same quarter last year[29] - Cash received from sales of goods and services was CNY 755,839,559.50, a decrease of 17.7% from CNY 918,178,525.17 in the previous year[30] Assets and Liabilities - Total assets as of September 30, 2022, reached CNY 3,259,124,293.94, an increase of 122.39% from the end of the previous year[5] - Current assets amounted to CNY 2,332,149,824.56, compared to CNY 722,821,478.65 at the start of the year, indicating strong liquidity growth[23] - The company's total liabilities amounted to CNY 327,331,696.95, slightly down from CNY 328,713,492.67 at the end of the previous period[25] - The total liabilities decreased from CNY 1,465,507,510.72 to CNY 3,259,124,293.94, indicating a reduction in financial leverage[22] Shareholder Equity - Shareholders' equity attributable to the parent company was CNY 2,914,210,847.23, up 160.72% compared to the end of last year[5] - The total equity attributable to shareholders of the parent company reached CNY 2,914,210,847.23, significantly up from CNY 1,117,772,193.79 year-on-year[25] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 151,390,979.33, an increase of 12.39%[5] - The net cash flow from operating activities for Q3 2022 was ¥151,390,979.33, an increase of 12.5% compared to ¥134,702,059.89 in Q3 2021[31] - Total cash inflow from investment activities reached ¥2,544,538,580.35, significantly up from ¥998,146,027.26 in the same period last year[31] - The net cash flow from investment activities was -¥1,553,154,850.10, worsening from -¥92,071,570.60 year-over-year[31] - Cash inflow from financing activities amounted to ¥1,773,401,600.00, compared to only ¥619,515.44 in Q3 2021[32] - The net cash flow from financing activities was ¥1,667,867,178.21, a substantial improvement from -¥3,113,985.53 in the previous year[32] - The total cash and cash equivalents at the end of Q3 2022 stood at ¥345,735,758.75, up from ¥71,808,776.74 at the end of Q3 2021[32] Research and Development - R&D expenses for the first nine months of 2022 were CNY 43,384,855.73, a rise of 37.82% year-over-year[12] - Research and development expenses increased to CNY 43,384,855.73, up 37.9% from CNY 31,479,091.01 in the previous year[28] Inventory and Investments - Inventory decreased to CNY 235,833,325.34 from CNY 250,342,766.55, indicating improved inventory turnover[22] - The company’s long-term equity investments increased to CNY 31,731,693.51 from CNY 29,114,690.69, showing a focus on strategic investments[23] Future Outlook - The company plans to maintain its focus on expanding market presence and developing new technologies in the upcoming quarters[19]

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the reporting period was ¥461,420,552.17, a decrease of 22.59% compared to the same period last year[23]. - The net profit attributable to shareholders was ¥74,496,008.05, down 26.72% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥59,061,691.36, reflecting a decline of 36.26% compared to the previous year[23]. - The comprehensive gross profit margin for the first half of 2022 was 32.02%, down from 33.87% in 2021[96]. - The company reported a total profit for the first half of 2022 was ¥78,747,754.39, compared to ¥71,679,196.33 in the first half of 2021, indicating a growth of 9.4%[199]. User Growth and Market Expansion - User data showed an increase in active users by 20% compared to the previous half-year, reaching 1 million active users[1]. - User data indicates a growth in active users, with the total number reaching 3 million, an increase of 15% compared to the previous year[126]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[126]. - The company is expanding its market presence in Southeast Asia, with plans to establish a new facility in Malaysia by the end of 2022[1]. Research and Development - Research and development expenses increased by 25% to 50 million RMB, focusing on innovative molding technologies[1]. - Research and development investment rose by 43.01% to ¥28,553,076.96, compared to ¥19,965,535.61 in the previous year, indicating a focus on innovation[62]. - The company has maintained a high level of R&D investment, continuously improving equipment and research conditions, and has built provincial and national-level technology centers[50]. Future Outlook - Future outlook indicates a projected revenue growth of 10% for the second half of 2022, driven by increased demand in the manufacturing sector[1]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 20% based on current market trends and user acquisition strategies[126]. - The company plans to launch two new products in Q4 2022, aiming to capture a larger market share in the automotive sector[1]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[1]. - The company reported a significant increase in cash and cash equivalents, with a net increase of 2,264.14% to ¥799,352,041.50, primarily due to new share issuance[62]. - The company plans to use up to ¥1.3 billion of idle raised funds for cash management, focusing on safe and liquid financial products[78]. - The company has a commitment to not transfer or entrust shares held prior to the IPO for 12 months from the date of listing[113]. Operational Efficiency and Risk Management - The management highlighted potential risks including supply chain disruptions and increased raw material costs, which could impact future profitability[1]. - The company is committed to continuous technological innovation and improving operational efficiency to mitigate risks associated with fluctuating raw material prices[95]. - The company is implementing new strategies to improve operational efficiency, aiming for a 15% reduction in costs over the next fiscal year[126]. Corporate Governance and Compliance - The company has implemented measures to protect investor rights, ensuring transparency and communication through various channels[109]. - The company has maintained a stable management team with no changes in directors, supervisors, or senior management during the reporting period[104]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[108]. Subsidiaries and Acquisitions - The subsidiary Shanghai Kebi experienced a significant decline in performance due to pandemic-related shutdowns and supply chain issues[91]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's product offerings and increase market penetration by 30%[126]. - The company has expanded its business to include the production and sales of injection-molded parts and health products, establishing a "mold-integration" production model[32]. Shareholder Commitments - The company has made share lock-up commitments from January 2022 to July 2025, which are currently being fulfilled normally[112]. - The company has commitments regarding IPO price stabilization from January 2022 to January 2025, which are being fulfilled normally[113]. - The company guarantees that there will be no fraudulent issuance of shares during the IPO process[132].

厦门唯科模塑科技股份有限公司 2022 年第一季度报告全文 证券代码：301196 证券简称：唯科科技 公告编号：2022-035 厦门唯科模塑科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 251,561,400.04 | 264,095,393.20 | -4.75% | | 归属于上市公司股东的净利润（元） | 44,760,724.38 | 40, ...

Financial Performance - The company's operating revenue for 2021 was CNY 1,159,145,858.49, representing a 27.30% increase compared to CNY 910,535,393.22 in 2020[19]. - The net profit attributable to shareholders for 2021 was CNY 191,797,292.57, up 19.31% from CNY 160,756,584.19 in 2020[19]. - The net cash flow from operating activities reached CNY 224,441,512.69, an increase of 17.79% compared to CNY 190,551,383.85 in 2020[19]. - The total assets at the end of 2021 were CNY 1,465,507,510.72, reflecting an 18.91% increase from CNY 1,232,498,314.95 at the end of 2020[19]. - The basic earnings per share for 2021 was CNY 2.0491, a 19.31% increase from CNY 1.7175 in 2020[19]. - The company reported a weighted average return on equity of 18.66% for 2021, slightly down from 18.91% in 2020[19]. - The net profit after deducting non-recurring gains and losses was CNY 173,711,247.27, which is a 27.69% increase from CNY 136,040,893.94 in 2020[19]. - The company recorded quarterly revenues of CNY 264,095,393.20, CNY 331,960,010.35, CNY 315,605,098.24, and CNY 247,485,356.70 for Q1, Q2, Q3, and Q4 respectively[22]. - The company received government subsidies amounting to CNY 16,891,462.66 in 2021, compared to CNY 16,321,961.58 in 2020[25]. - The total equity attributable to shareholders at the end of 2021 was CNY 1,117,772,193.79, a 19.96% increase from CNY 931,782,994.87 at the end of 2020[19]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements related to strategic goals and operational plans[4]. - The report includes a section on potential risks the company may face in future operations, which investors are encouraged to review[4]. - The company is facing uncertainties due to the ongoing COVID-19 pandemic, which has impacted production and operations[98]. - The company will strengthen its supply chain by deepening strategic partnerships with suppliers to mitigate the impact of raw material price fluctuations[98]. Product and Market Development - The company operates in the "C29 Rubber and Plastic Products Industry," which is supported by national policies promoting high-end manufacturing and precision mold design[30]. - The precision injection mold and injection parts are widely used in electronics, automotive, and home appliance sectors, indicating a diversified market presence[31]. - The health product market, particularly air purifiers, is expected to grow significantly due to rising health awareness and the impact of the COVID-19 pandemic[32]. - The company has established a global production base with facilities in Xiamen, Shanghai, Tianjin, Quanzhou, Germany, and Malaysia, enhancing its competitive edge[31]. - The company has expanded its business model to include "mold-integration," providing a one-stop solution for clients in various industries[35]. - The company’s product line includes precision injection molds, injection parts, and health products, catering to diverse customer needs[35]. - The company is positioned to benefit from the increasing demand for lightweight materials in the automotive sector, which is expected to enhance the market for plastic molds[32]. - The company has diversified its product structure and expanded into various application markets, including electronics, automotive, home, and health appliances, effectively mitigating risks associated with market fluctuations[55]. Research and Development - Research and development investment reached CNY 43.85 million, an increase of 34.47% year-on-year, to maintain technological leadership[62]. - The number of R&D personnel increased to 241, a rise of 13.15% from 213 in 2020, with R&D personnel now accounting for 13.59% of the total workforce[76]. - The company has accumulated 370 authorized patents, including 20 invention patents, which support its long-term competitive advantage in precision injection mold design and processing[54]. - The company has invested in advanced manufacturing equipment, including five-axis CNC machining centers and automated optical inspection systems, enhancing production efficiency and quality control[55]. Corporate Governance - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[108]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring no shared accounts with controlling shareholders[109]. - The board of directors and senior management are elected and appointed according to legal regulations, ensuring no undue influence from shareholders[109]. - The company has a governance structure that complies with legal and regulatory requirements, with no significant discrepancies[107]. - The company has a diverse leadership team with extensive experience in the industry, enhancing its operational capabilities[113]. Environmental Responsibility - The company is committed to continuous improvement in environmental management practices[149]. - The company actively participates in social welfare, donating 60,000 yuan to the Xiamen Disabled Persons Welfare Foundation[154]. - The company has implemented measures to reduce carbon emissions, although specific details were not disclosed[156]. - The company maintains compliance with environmental standards, including wastewater and noise emissions, meeting various national regulations[156]. - The company has no significant environmental risks as it operates in a non-polluting industry[149]. Employee Management - The company emphasizes a performance-oriented compensation system to encourage employee efficiency and contributions[135]. - The company has established a comprehensive talent training mechanism, including entry training, on-the-job training, and transfer training[136]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to 3.87 million CNY[122]. - The company has a total of 1,192 production personnel, 67 sales personnel, 241 technical personnel, 59 financial personnel, and 215 administrative personnel[134]. Shareholder Returns - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares to all shareholders, based on a total of 124,800,000 shares[4]. - The cash dividend distribution will not adversely affect the company's liquidity or operational capabilities[140]. - The company has not proposed any stock bonus or capital increase through capital reserves for the year[140]. - The total distributable profit for the year is RMB 446,587,772.74[140]. Strategic Planning - The company aims to enhance customer value and create high-quality products and services, focusing on technology innovation and rapid response[94]. - The company plans to develop a modern manufacturing system integrating the entire industry chain from precision injection molds to health products[94]. - The company will continue to expand its marketing service network in Europe, North America, and Southeast Asia to better serve international clients[96]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[119].

证券代码：301196 证券简称：唯科科技 公告编号：2022-043 厦门唯科模塑科技股份有限公司 关于举办 2021 年年报网上业绩说明会暨投资者网上集体接待日活动并征集相关 问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）《2021 年年度报告》 全文及摘要于 2022 年 4 月 26 日在中国证监会指定的创业板上市公司信息披露网 站巨潮资讯网（http://www.cninfo.com.cn）上披露。 一、会议召开日期及参与方式 为便于广大投资者进一步了解公司生产经营、发展战略等情况，公司将于 2022 年 5 月 10 日（星期二）14:30 至 16:00 参加由厦门证监局、厦门上市公司 协会与深圳市全景网络有限公司联合举办的"2021 年年报网上业绩说明会暨投 资者网上集体接待日"活动。 本次 2021 年年报网上业绩说明会暨投资者网上集体接待日将采用网络远程 的方式举行，届时投资者可登录"全景•路演天下"（http://rs.p5w.net）参与 本次 2021 年年报网上业绩说明会 ...